Group 1 - The core point of the article is that Jiuan Medical (stock code: 002432) reported on September 12 that the number of shareholders as of September 10, 2025, is approximately 73,100 households [1]

Core Viewpoint - The company has demonstrated a strong commitment to maintaining its market value through multiple share buybacks, despite short-term stock price fluctuations influenced by market and other factors [1] Group 1: Company Performance - The company's Continuous Glucose Monitoring (CGM) products are being actively promoted, indicating a focus on innovation and product development [1] - The internet healthcare segment is expanding, contributing to increasing revenue [1] - The company benefits from stable and continuous profits and cash flow through annual asset allocation [1] Group 2: Management Perspective - The management believes that the stock price will reflect the company's fundamentals in the long term [1] - The company is committed to improving operational management to enhance overall company value [1]

Core Viewpoint - Jiuan Medical (002432) addressed investor inquiries on its investment projects and IPO plans during a recent interaction on the investor relations platform [1] Group 1: Company Response - The company acknowledged investor concerns regarding repetitive responses and emphasized the importance of reviewing past disclosures for information on investments and IPOs [1] - Jiuan Medical referred investors to the 2025 semi-annual report's management discussion and analysis section for details on collaborations with professional investors and direct investment activities [1] - The company suggested that investors check public information platforms for details on the funds it has invested in and their final allocations [1]

Group 1 - The company has invested an amount equivalent to 30 million USD in the entities related to "The Dark Side of the Moon" [1] - Currently, the company has no plans for an H-share listing, but will fulfill information disclosure obligations if there are any related developments [1]

Group 1 - The company has opened an investment office in New York, which has a minimal impact on its operating performance and does not meet the disclosure standards [1]

证券日报网讯九安医疗（002432）9月9日在互动平台回答投资者提问时表示，公司的薪酬体系从开展第 一次股票期权激励计划开始，就已经转变为现金+股权的薪酬包模式，期权激励计划和持股计划均是公 司员工薪酬体系的一部分，公司在现金部分的标准相较于同行业、同规模的公司属于较低的，股权部分 是为了更好的实现股东、公司和员工三方的利益绑定。请投资者理解，公司希望通过员工参与的股权部 分让员工体会到其工作的投入对公司价值的影响，提升员工的工作积极性，这会直接给公司经营基本面 带来价值。高管取得的股权激励情况，公司已在激励方案中进行了披露。 ...

Group 1 - The company, Jiann Medical, responded to investor inquiries on September 9 regarding its historical cash dividend situation, indicating that investors should pay attention to the company's equity distribution implementation announcement [2]

Core Viewpoint - The company is enhancing its brand recognition and market presence in the home respiratory virus screening sector through the development of single-test reagent kits and plans to expand its product offerings in the IVD field [1] Group 1 - The company has established strong brand awareness by launching single-test reagent kits, which has effectively opened up the market [1] - Following the introduction of the triple-test product, the company aims to continuously expand the range of detectable virus sequences [1] - The company is committed to ongoing research and development efforts to diversify its OTC/POC in vitro diagnostic products [1]

Core Viewpoint - The company is optimistic about the market prospects for diabetes-related products, given the increasing global prevalence of diabetes and the relatively low competition in the market [1] Industry Summary - Diabetes is one of the most prevalent chronic diseases globally, with the number of affected individuals reaching 529 million in 2021 and projected to rise to 1.31 billion by 2050, indicating a significant market opportunity [1] - The company is actively advancing its "Internet + Healthcare" strategy, focusing on the new "O+O" model for diabetes care, which has been implemented in approximately 50 cities across China and 424 hospitals, managing over 366,000 diabetes patients [1] - In the United States, the company has partnered with around 74 clinics and 394 doctors, providing care to approximately 21,000 patients, with substantial growth in patient numbers and related revenue in recent years [1] - The U.S. healthcare system has begun reimbursing for internet healthcare services, and similar policies are gradually being established in China [1]

Core Viewpoint - The company, Jiuan Medical (002432), is focused on asset preservation and appreciation, leveraging a professional asset management team to enhance its investment strategies [1] Group 1: Asset Management Strategy - The company has established a dedicated asset management team with experienced professionals in the field [1] - Jiuan Medical is actively engaging in large asset allocation business primarily through its wholly-owned subsidiary, Jiuan Hong Kong [1] Group 2: Financial Performance - The fair value changes and investment income generated from the investment business are classified as recurring gains [1] - The large asset allocation business is expected to significantly boost the company's net profit attributable to shareholders in the first half of 2025, with an anticipated increase of 52.91% compared to the same period last year [1]